Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks Announces Participation in Upcoming Investor Conferences

GlobeNewswire 1 day ago

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

GlobeNewswire 1 day ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

GlobeNewswire November 5, 2024

Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results

GlobeNewswire October 31, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

GlobeNewswire October 29, 2024

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

GlobeNewswire October 25, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

GlobeNewswire October 21, 2024

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

GlobeNewswire October 10, 2024

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

GlobeNewswire September 18, 2024

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

GlobeNewswire September 3, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

GlobeNewswire August 22, 2024

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

GlobeNewswire August 1, 2024

Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire August 1, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

GlobeNewswire July 30, 2024

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

GlobeNewswire July 25, 2024

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

GlobeNewswire July 22, 2024

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

GlobeNewswire July 11, 2024

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

GlobeNewswire June 17, 2024

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

GlobeNewswire June 10, 2024

Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ZYME

Accesswire May 31, 2024